RDG Dimer Peptide for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory agents for treating inflammatory diseases, such as arthritis, often have significant side effects and toxicity, limiting their efficacy and safety, necessitating the development of novel therapeutic agents with improved therapeutic effects and reduced side effects.
Innovation Solution
A dimeric peptide composed of amino acids, specifically the RDG dimer, is developed, which exhibits excellent anti-inflammatory activity by inhibiting inflammatory cytokine generation and is formulated for various administration methods, including pharmaceutical compositions and health functional foods, to treat a range of inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-inflammatory agents (NSAIDs, steroids) are used to treat inflammatory diseases, then anti-inflammatory efficacy is improved, but safety and side effects worsen
Solution Approach 1:
The patent segments the therapeutic function into two distinct components: a peptide moiety (RDG sequence) that provides targeted anti-inflammatory activity through specific biological interactions, and a carbohydrate moiety that provides solubility, stability, and reduced immunogenicity. This segmentation allows the drug to achieve efficacy while minimizing the harmful side effects associated with conventional NSAIDs and steroids.
Solution Approach 2:
The patent employs a composite material strategy by conjugating a peptide sequence (RDG) with a carbohydrate moiety to create a hybrid therapeutic agent. This composite structure combines the advantages of peptides (high specificity and potency) with the advantages of carbohydrates (solubility, stability, and biocompatibility), thereby achieving effective anti-inflammatory treatment with reduced toxicity and side effects.
2Reliability
If long-term anti-inflammatory therapy is administered, then disease control is improved, but gastrointestinal side effects and gastric ulcers worsen
Solution Approach 1:
The carbohydrate moiety acts as an intermediary that mediates between the peptide's anti-inflammatory activity and the body's physiological systems. This intermediary structure improves the drug's solubility and stability, enables controlled delivery, and reduces direct irritation to the gastrointestinal tract, allowing for safe long-term therapy while maintaining effective disease control.
Solution Approach 2:
The patent changes the physical and chemical parameters of the therapeutic agent by conjugating the peptide with carbohydrate moieties. This modification alters the drug's solubility, stability, and bioavailability parameters, enabling long-term administration without the gastrointestinal toxicity and ulceration problems associated with conventional anti-inflammatory agents.
3Reliability
If high doses of anti-inflammatory agents are used to maximize therapeutic effect, then inflammation reduction is improved, but toxicity and side effects worsen
Solution Approach 1:
The patent applies local quality by designing a peptide sequence (RDG) that provides highly specific and localized anti-inflammatory activity at the target site. This localized action allows effective inflammation reduction at lower overall doses, thereby minimizing systemic toxicity and side effects while maintaining therapeutic efficacy.
Data Source
AI summary
Provided is a peptide for preventing or treating inflammatory diseases and a use thereof. According to a novel dimeric peptide according to the present invention, it is possible to not only exhibit an excellent therapeutic effect through anti-inflammatory action but also have a very small-sized peptide, thereby minimizing side effects due to the administration of external substances and will be expected to be used as an active substance that can replace existing therapeutic agents for inflammatory diseases.